Clinical Trials
18
Active:0
Completed:6
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:8
Phase 2:4
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (44.4%)Not Applicable
5 (27.8%)Phase 2
4 (22.2%)Early Phase 1
1 (5.6%)Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
Not Applicable
Recruiting
- Conditions
- Autoimmune Disease
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06993493
- Locations
- 🇨🇳
Beijing Gobroad Brond Hospital, Beijing, Beijing, China
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
Not Applicable
Recruiting
- Conditions
- Autoimmune Disease
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06983964
- Locations
- 🇨🇳
Beijing Gobroad Brond Hospital, Beijing, Beijing, China
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
Not Applicable
Recruiting
- Conditions
- Light Chain Amyloidosis
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06983951
- Locations
- 🇨🇳
Beijing Gobroad Brond Hospital, Beijing, Beijing, China
A Study of CAR-T Cells Targeting Autoimmune Diseases
Not Applicable
Not yet recruiting
- Conditions
- Autoimmune Diseases
- Interventions
- Drug: CAR-T
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06661811
- Locations
- 🇨🇳
Beijing Gaobo Boren Hospital, Beijing, China
Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19
Not Applicable
Completed
- Conditions
- Hematological DisordersCOVID-19
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Beijing Boren Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT05675943
- Locations
- 🇨🇳
Beijing Boren Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found